Stockscreener 앱 받기
0.7023
0.23%
-0.0067
시간 외 거래:
.69
-0.0123
-1.75%
전일 마감가:
$0.709
열려 있는:
$0.6877
하루 거래량:
153.47K
Relative Volume:
0.63
시가총액:
$53.82M
수익:
$241.00K
순이익/손실:
$-23.76M
주가수익비율:
-0.5669
EPS:
-1.2389
순현금흐름:
$-18.38M
1주 성능:
-4.41%
1개월 성능:
+4.86%
6개월 성능:
-11.43%
1년 성능:
-56.60%
1일 변동 폭
$0.6877
$0.72
1주일 범위
$0.6877
$0.7398
52주 변동 폭
$0.3625
$1.89
Envoy Medical Inc Stock (COCH) Company Profile
명칭
Envoy Medical Inc
전화
651-361-8000
주소
4875 WHITE BEAR PARKWAY, WHITE BEAR LAKE
Compare COCH vs ABT, SYK, MDT, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
COCH
Envoy Medical Inc
|
0.70 | 54.51M | 241.00K | -23.76M | -18.38M | -1.2389 |
ABT
Abbott Laboratories
|
86.66 | 152.25B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
312.95 | 121.33B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
77.59 | 100.91B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
57.66 | 85.88B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
87.56 | 49.39B | 6.30B | 1.07B | 1.09B | 1.8406 |
Envoy Medical Inc Stock (COCH) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-31 | 개시 | H.C. Wainwright | Buy |
| 2024-06-24 | 개시 | Ascendiant Capital Markets | Buy |
Envoy Medical Inc 주식(COCH)의 최신 뉴스
Envoy Medical Announces New Patents Expanding Intellectual Property Portfolio in Fully Implanted Hearing Technology - Florida Hospital News and Healthcare Report
COCH Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Positive SurpriseLow Estimate Range - Newser
COCH Q1 2026 Earnings: Narrower-Than-Expected Loss Signals Progress, Though Revenue Absence Raises QuestionsHigh Growth Earnings - Newser
Envoy Medical Inc. (COCH) Q1 2026 Earnings: Strong EPS Beat Amidst Pre-Revenue StageEarnings Per Share - Newser
Envoy Medical Q1 2026 Earnings: EPS Surprises to the Upside Despite No Revenue, Stock DeclinesTrading Community Hub - Newser
COCH Q1 2026 Earnings: Significant EPS Beat Amid Revenue UncertaintyElite Trading Signals - Newser
Envoy Medical Granted Extension to Regain Nasdaq Compliance - TipRanks
Envoy Medical Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Envoy Medical (NASDAQ: COCH) granted more time to meet Nasdaq $1 bid rule - Stock Titan
COCH Q1 2026 Earnings: Narrower Loss Beats Estimates as Envoy Medical AdvancesReturn On Assets - Newser
COCH Q1 2026 Earnings: EPS Beats Estimates Despite Pre-Revenue Status, Stock DeclinesShared Buy Zones - Newser
Envoy Medical shareholders approve plan amendments and board elections at annual meeting By Investing.com - Investing.com South Africa
Envoy Medical shareholders approve plan amendments and board elections at annual meeting - Investing.com Australia
Envoy Medical Shareholders Expand Equity and Governance Plans - TipRanks
Envoy Medical (NASDAQ: COCH) holders back larger equity and stock purchase plans - Stock Titan
Envoy Medical (COCH): Nantahala reports 9.99% position in company - Stock Titan
[SCHEDULE 13G] Envoy Medical, Inc. Passive Investment Disclosure (>5%) - Stock Titan
TradingKey - TradingKey
Envoy Medical Flags Limited Risk Detail, Urges Investors to Review 2026 Form 10-K for Key Uncertainties - TipRanks
ENVOY MEDICAL (COCH) insiders report 2.46M warrants, 3.10% stake - Stock Titan
Envoy Medical, Inc. Q1 2026 Financial Report: Earnings, Balance Sheet, and FDA-Approved Hearing Devices Overview - Minichart
Envoy Medical completes pivotal trial enrollment, raises $78m By Investing.com - Investing.com South Africa
Envoy Medical Achieves Pivotal Trial Milestone and Secures $78M Financing for Fully Implanted Cochlear Implant FDA Approval Progress - Minichart
Envoy Medical completes pivotal trial enrollment, raises $78m - Investing.com
Envoy Medical, Inc. 1Q 2026: Revenue $39K, Net income ($5.7M), EPS ($0.08) — 10-Q Summary - TradingView
Envoy Medical, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Envoy Medical (NASDAQ: COCH) Q1 2026 loss narrows after $27.8M raise - Stock Titan
Envoy Medical reports Q1 2026: $39k revenue, $5.96M operating expenses, $4.35M net loss - TradingView
Envoy Medical Reports Landmark Accomplishments, Advancing Toward FDA Approval of First-of-Its-Kind Fully Implanted Cochlear Implant - marketscreener.com
Envoy Medical (NASDAQ: COCH) boosts cash to $25M as pivotal trial fully enrolls - Stock Titan
56 people get first-of-its-kind fully implanted cochlear implant - Stock Titan
COCHW (Envoy Med) warrant earnings report draws market scrutiny amid limited financial disclosure.Margin Expansion - newser.com
Envoy Medical Secures Additional Patent Protection for Its Growing Patent Portfolio - TMX Newsfile
Envoy Medical Reports on First Quarter 2025 Results - TMX Newsfile
Envoy Medical Corporation and Anzu Special Acquisition Corp I Complete Business Combination - TMX Newsfile
Envoy Medical to Participate in the 37th Annual ROTH Conference - TMX Newsfile
Envoy Medical Reports Third Quarter 2025 Financial and Operational Results - Quantisnow
Envoy Medical's Pivotal Clinical Trial for Fully Implanted Acclaim(R) Cochlear Implant Remains On Track After First Month Follow-Up - TMX Newsfile
Envoy Medical (COCH) Expected to Announce Earnings on Thursday - MarketBeat
Envoy Medical presents early data from cochlear implant trial By Investing.com - Investing.com Nigeria
Envoy Medical presents early data from cochlear implant trial - Investing.com
Envoy Medical Highlights First Clinical Data Presentations from Pivotal Clinical Study of Fully Implanted Acclaim(R) Cochlear Implant - Yahoo Finance
Envoy Medical Inc expected to post a loss of 14 cents a shareEarnings Preview - TradingView
Envoy Medical Reaches Critical Milestone in Pivotal Clinical Trial of Fully Implanted Acclaim(R) Cochlear Implant - Florida Hospital News and Healthcare Report
Envoy Med (COCH) Stock Industry Update (Selling Pressure) 2026-04-27Shared Momentum Picks - newser.com
Envoy Medical shares crater after announcing $4 million direct offering - MSN
Envoy Medical Achieves Clinical Trial Milestone and is Optimistic About Expansion into Final Stage of Trial - TMX Newsfile
COCH (Envoy Medical Inc.) reports Q3 2025 EPS below analyst estimates, as shares rise one percent in daily trading.Special Dividend - Cổng thông tin điện tử tỉnh Tây Ninh
A fully implanted cochlear implant clears key step in 56-patient study - Stock Titan
COCHW | Envoy Medical, Inc Warrant Insider Trading - Quiver Quantitative
Envoy Medical Inc (COCH) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Envoy Medical Inc 주식 (COCH) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Potashnick Robert | Interim CFO |
Feb 12 '26 |
Buy |
0.40 |
212,500 |
85,000 |
212,500 |
| Kantor Susan | Director |
Feb 12 '26 |
Buy |
0.40 |
96,150 |
38,460 |
174,037 |
| BRYNELSEN CHARLES | Director |
Feb 12 '26 |
Buy |
0.40 |
1,000,000 |
400,000 |
1,050,000 |
| Lucas Brent T. | Chief Executive Officer |
Feb 12 '26 |
Buy |
0.40 |
62,500 |
25,000 |
297,090 |
| TAYLOR GLEN A | 10% Owner |
Feb 12 '26 |
Buy |
0.40 |
18,750,000 |
7,500,000 |
21,703,607 |
| Patel Mona Chetan | Director |
Jun 11 '25 |
Buy |
1.47 |
2,500 |
3,675 |
20,000 |
| Patel Mona Chetan | Director |
Jun 06 '25 |
Buy |
1.46 |
10,000 |
14,600 |
17,500 |
| BRYNELSEN CHARLES | Director |
May 27 '25 |
Buy |
1.65 |
35,000 |
57,673 |
50,000 |
1.35%
2.06%
자본화:
|
볼륨(24시간):